Liquidators for Dick Smith don’t want potential group members in two class actions against the failed retailer to learn about a new registration deadline by email, saying it would amount to spam and harassment.
Hyundai Engineering and Steel Industries has been granted almost $5.6 million in compensation in a case against Australian company Alfasi Steel over construction delays on Sydney’s International Convention Centre.
A judge has said a case filed by Hyundai Engineering & Steel Industries to enforce a $7.9 million arbitration award against Alfasi Steel over the delayed construction of Sydney’s International Conference Centre can move forward even though Alfasi has gone into administration.
Two ‘sham letters’ produced by a senior manager of national car repair franchise Ultra Tune led both the ACCC and the court ‘down the garden path,’ a Federal Court judge heard Thursday.
The final day of trial in the ACCC’s case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as ‘onerous’ a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant ‘inherited’ from Novartis.
The first day of a liability hearing in a consumer case over GlaxoSmithKline’s marketing for its popular Voltaren products has seen an ACCC witness deflect accusations the regulator was vague about its misleading packaging concerns, placing the blame squarely on the pharmaceutical giant.
A judge has stayed a case brought by Hyundai to enforce a $7.9 million arbitration award against Alfasi Steel related to the delayed construction of Sydney’s International Conference Centre until a challenge to the award in Singapore’s High Court concludes.
ASX-listed Servcorp has settled court action by the consumer watchdog over unfair terms in its small business contracts that shielded the office space provider from liability and gave it unilateral power to terminate agreements with customers.
GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
The ACCC will face a test of its ability to win misuse of market power cases when a long-awaited judgment is handed down this week in the regulator’s appeal of a ruling dismissing its case alleging Pfizer misused its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.